Canterbury Park enters into agreement to convert its notes of Paragon Pharmacies Limited



    WINNIPEG, July 31 /CNW/ - Canterbury Park Capital GP L.P., on behalf of
private equity funds of which it is the general partner ("Canterbury"),
announced today that it has entered into an agreement with Paragon Pharmacies
Limited (PGN - TSXV) ("Paragon"), to convert its $20 million of Paragon notes,
accrued interest, accrued interest adjustment and conversion inducement fee
into additional common Shares ("Shares") of Paragon at a combined average
price of approximately $0.65 per share ( the "Proposed Transaction" ).
Specifically, Canterbury would:

    
    -   Convert the $20,000,000 principal convertible notes (the "Notes") it
        holds to Paragon shares at $0.8028 per share;

    -   Receive accrued interest and accrued interest adjustment on the
        Notes, in the aggregate amount of $1,775,003, via additional Paragon
        shares at $0.35 per share; and

    -   Receive a conversion inducement fee equal to forgone interest for
        early conversion at the rate otherwise payable to the scheduled
        maturity of May 2, 2009 and an agreed interest adjustment amount, in
        the aggregate amount of $2,871,988, via additional Paragon shares at
        $0.35 per share.
    

    The Proposed Transaction is conditional on, among other things, reaching
a satisfactory agreement with Paragon's bank lender, approvals of other
creditors, completion of the Autonomy Transaction described in the
Corporation's press release of January 31, 2008, satisfactory completion of
due diligence by Canterbury Park and all requisite regulatory approvals,
including approval of the TSX Venture Exchange and the Competition Bureau. A
special meeting of Paragon shareholders has been called for August 29, 2008 to
consider the Autonomy Transaction. Meeting materials are expected to be mailed
to Paragon shareholders for that meeting shortly.
    This transaction would result, assuming an August 31, 2008 closing date,
in Canterbury acquiring, an additional 24,912,805 Shares.
    Prior to the proposed acquisition of these additional Shares, Canterbury
owned 10,072,455 Shares, and may have been deemed to own 36,860,260 Shares,
representing approximately 49.7% of the issued and outstanding Shares. In the
event of the completion of the proposed acquisition and the Autonomy
Transaction, Canterbury would own approximately 48,262,377 Shares and may be
deemed to own approximately 1,875,000 additional Shares, representing
approximately 63% of the issued and outstanding Shares of the Company,
calculated as if the warrants to acquire 1,875,000 additional Shares held by
Canterbury were fully exercised.
    The proposed transactions are set out in the terms of a Note Conversion
Agreement between Canterbury and Paragon. Given the conditions that remain to
be satisfied, there can be no assurance that closing will occur. Following
closing, Canterbury and Paragon will continue to be parties to a number of
agreements, including an Advisory Agreement, whereby Canterbury provides
advice to Paragon in return for a fee, and a Registration Rights Agreement. As
well, Canterbury nominees will comprise the majority of Paragon's Board
members.
    The Shares would, if acquired, be acquired from treasury. Canterbury
would acquire and hold all of its Shares for investment purposes, and may
acquire further Shares, or dispose of its holdings of Shares, both as
investment conditions warrant.

    Canterbury is located at c/o Canterbury Park Management Inc., Suite 300,
1001 Corydon Avenue, Winnipeg Manitoba, R3M 0B6.





For further information:

For further information: Bruce Warnock, Tel: (204) 954-5104, Fax: (204)
954-5185

Organization Profile

PARAGON PHARMACIES LIMITED

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890